Tyrosine kinase inhibitor research presses on despite halted clinical trial.

Journal of the National Cancer Institute

Volumn 92, Issue 12, 2000, Pages 967-969

  Garber, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; NEW DRUG; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; SEMAXANIB; VASCULOTROPIN RECEPTOR;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; ONCOGENE SRC; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SIGNAL TRANSDUCTION;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE III; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; GENES, SRC; HUMANS; INDOLES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 0034697592     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.12.967     Document Type: Article

References (0)